In summary, these clinical findings mirror the effects of RBM10 deficiency that we observed in in vitro and in vivo in the preclinical models, namely diminished initial tumor cell apoptosis and EGFR TKI response, and complement the independent clinical data described above (Figure 4A and Table 3). This evidence concerns the gene RBM10 and neoplasm.